An observational study in Milk Expression, Breast, sponsored by University of Minnesota. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by University of Minnesota · Observational
Investigate the pharmacokinetics of Liposomal Bupivacaine and its excretion in breast milk in patients undergoing TAP block after their scheduled C -section delivery
University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Pregnant patients undergoing scheduled C-section delivery
Exclusion Criteria:
blood and milk samples will be obtained from those subjects after TAP block
milk plasma ratio
AUC for the milk/plasma drug ratio
Time frame: 72 hours
AUC of plasma
AUC for drug concentration in plasma
Time frame: 72 hours
AUC of milk
AUC for drug concentration in milk
Time frame: 72 hours
Plan to share: No
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Minnesota